Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
CAT-192 APPEARS TOLERABLE
Cambridge Antibody Technology and Genzyme Corp. announced preliminary results from a Phase I/II clinical trial of CAT-192, a human anti-TGF(Beta)1 monoclonal antibody. The primary objective of the trial was to assess the safety, tolerability, and pharmacokinetics of CAT-192 in patients suffering from diffuse systemic sclerosis.
Recent Videos
Related Content
